Antibody-dependent cellular cytotoxicity (ADCC) is a key immunological mechanism for antibodies. For the previous years, ADCC-enhanced therapeutic antibodies have been proven to have extraordinary anti-cancer properties in vivo. Characterizing ADCC activity and figuring out how it affects clinical effectiveness are crucial steps in the study process. Creative Biolabs is dedicated to creating next-generation therapeutic antibodies with ADCC enhancements for our clients by utilizing our extensive expertise in antibody engineering and glycosylation management. Check more details: Therapeutic ADCC⁺ Biobetter Antibody Analysis
